Pfizer has become the first pharmaceutical company to agree to the Trump administration's most-favored nation pricing initiative, committing to sell select medicines in the United States at prices comparable to other developed countries. As part of the deal, Pfizer will launch a direct-to-consumer website, TrumpRx, offering certain medications at an average discount of 50% or more. The agreement provides Pfizer with a three-year reprieve from threatened tariffs and reflects ongoing efforts to lower drug prices while balancing global market strategies.